微电生理收盘下跌2.89%，滚动市盈率139.31倍，总市值91.63亿元

Core Viewpoint - The company, 微电生理, is experiencing a decline in stock price and has a high price-to-earnings (PE) ratio compared to the industry average, indicating potential overvaluation in the market [1][3]. Company Overview - 微电生理 specializes in the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2]. - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, focusing on precise interventional navigation [2]. Product Portfolio - Key products include the Columbus 3D cardiac electrophysiology mapping system, EasyFinder3D magnetic positioning adjustable mapping catheter, and various disposable mapping and ablation catheters [2]. - The company’s cryoablation devices and balloon-type cryoablation catheters have been recognized in the 2024 Shanghai "New Excellent Drugs and Devices" product directory [2]. Financial Performance - In Q1 2025, the company reported revenue of 1.04 billion yuan, a year-on-year increase of 16.77%, and a net profit of 178.7 million yuan, reflecting a significant year-on-year growth of 328.63% [3]. - The gross profit margin for the company stands at 60.56% [3]. Market Position - As of June 10, the company's stock price closed at 19.47 yuan, with a rolling PE ratio of 139.31, significantly higher than the industry average of 51.00 and the median of 37.03 [1][3]. - The total market capitalization of 微电生理 is 9.163 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders is 7,764, a decrease of 209 from the previous count, with an average holding value of 352,800 yuan per shareholder [1].